🟢 Icecure Medical is trading 10% up in pre-market after China’s NMPA approved ProSense for commercialization

Icecure Medical is trading at $2.43, up 9.99%, after China’s NMPA approved ProSense and associated cryoprobes for commercialization.

• The Class III medical-device approval expands IceCure Medical’s addressable market.
• The September 10 regulatory milestone remains the clearest company-specific catalyst; no newer announcement was identified for September 14.
• The move is notable despite weaker pre-market broader-market sentiment, suggesting company-specific strength and supporting the positive reaction following the September 11 session.